Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: Sub-analysis of a double-blind study

Current Medical Research and Opinion

Volumn 22, Issue 11, 2006, Pages 2209-2219

  Andrezina, Raisa ^a   Marcus, R N ^b   Oren, D A ^b   Manos, G ^b   Stock, E ^b   Carson, W H ^c   McQuade, R D ^c  

^a Department of Psychiatry   (Latvia)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Aggression; Antipsychotic; Atypical; Emergency

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE; HALOPERIDOL; PLACEBO;

ADULT; AGITATION; AKATHISIA; ANXIETY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; HALLUCINATION; HEADACHE; HUMAN; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TREMOR; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MULTICENTER STUDIES; PIPERAZINES; PSYCHOMOTOR AGITATION; QUINOLONES; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 33751247015     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X148445     Document Type: Conference Paper

References (32)

1. Binder RL, McNiel DE. Emergency psychiatry: contemporary practices in managing acutely violent patients in 20 psychiatric emergency rooms. Psychiatr Serv 1999;50:1553-4
2. Pilowsky LS, Ring H, Shine PJ, et al. Rapid tranquillisation. A survey of emergency prescribing in a general psychiatric hospital. Br J Psychiatry 1992;160:831-5
3. Kunik ME, Yudofsky SC, Silver JM, et al. Pharmacologic approach to management of agitation associated with dementia. J Clin Psychiatry 1994;55(Suppl):13-7
4. San L, Arranz B, Escobar R. Pharmacological management of acutely agitated schizophrenic patients. Curr Pharm Des 2005;11:2471-7
5. Kapur S, Arenovich T, Agid O, et al. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 2005;162:939-46
6. Battaglia J. Pharmacological management of acute agitation. Drugs 2005;65:1207-22
7. Hughes DH, Kleespies PM. Treating aggression in the psychiatric emergency service. J Clin Psychiatry 2003;64:10-5
8. Andrezina R, Josiassen R, Marcus R, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with IM haloperidol. Psychopharmacology 2006;88:281-92
9. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-8
10. Wright P, Meehan K, Birkett M, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther 2003;25:1420-8
11. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis [Ziprasidone I.M. Study Group]. J Clin Psychiatry 2000;61:933-41
12. Brook S, Walden J, Benattia I, et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl) 2005;178:514-23
13. Mendelowitz AJ. The utility of intramuscular ziprasidone in the management of acute psychotic agitation. Ann Clin Psychiatry 2004;16:145-54
14. Jann MW, Bunt RM. Switching antipsychotic drugs: a pharmacokinetic, pharmacodynamic, and practical perspective. Psychopharmacol Bull 2002;36:22-41
15. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-71
16. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an anti-psychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90
17. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-37
18. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-56
19. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36
20. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65:47-56
21. Kostic D, Oren D, Marcus R, et al. Intramuscular aripiprazole and lorazepam vs. placebo for agitation in acute mania. Eur Neuropsychopharmacol 2005;15(Suppl 3):S510, P3.126
22. Modell S, Daniel D, Stock E, et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. Int J Neuropsychopharmacol 2004;7(Suppl 1):S417
23. APA. Diagnostic and statistical manual of mental disorders (DSM-IV), 4th ed. Washington (DC): American Psychiatric Association; 1994
24. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999;45:403-11
25. Guy W. Clinical Global Impressions (CGI). ECDEU assessment manual for psychopharmacology [US Department of Health, Education, and Welfare Publication (ADM) 76-338]. Rockville (MD): National Institute of Mental Health; 1976. p. 218-22
26. Battaglia J, Lindborg SR, Alaka K, et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 2003;21:192-8
27. Corrigan JD, Bogner JA. Factor structure of the agitated behavior scale. J Clin Exp Neuropsychol 1994;16:386-92
28. Dillenschneider A, Oren D, Marcus R, et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. Eur Neuropsychopharmacol 2005;15(Supp 3):S509
29. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149-51
30. Daniel DG, Zimbroff DL, Swift RH, et al. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol 2004;19:9-15
31. Zyprexa, Zyprexa United States package insert. Indianapolis (IN): Eli Lilly and Co; 2005
32. Geodon, Geodon package insert. New York (NY): Pfizer; 2003